March 31, 2025
TOPLINE: The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine was safe and well tolerated and offered protection against mpox in people living with HIV, individuals on HIV […]
March 27, 2025
TOPLINE: Switching from a boosted protease inhibitor (bPI)–based regimen to bictegravir plus emtricitabine plus tenofovir alafenamide (B/F/TAF) maintained virological suppression over 48 weeks in patients with […]
March 24, 2025
GENEVA (Reuters) -There could be 2,000 new HIV infections a day across the world and a ten-fold increase in related deaths if funding frozen by the […]
March 20, 2025
The double dosing of dolutegravir and bictegravir HIV regimens in combination with rifampicin-based therapies for tuberculosis (TB) in people living with HIV showed similarly low levels […]
March 19, 2025
Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), based on data from 108 individuals. Previous research has […]
March 17, 2025
TOPLINE: Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. METHODOLOGY: Researchers conducted a randomized, […]
March 13, 2025
Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with […]
February 26, 2025
Cabotegravir and rilpivirine (cabenuva), the only complete HIV treatment regimen delivered by injection, could be given by intramuscular injection to the thigh rather than the gluteal […]
February 24, 2025
A cardiovascular risk calculator routinely used by physicians underestimates the risk for women and Black people living with HIV in high-income countries, while it overestimates risk […]